XYLEM
The International Water Association (IWA) and global water technology company, Xylem (NYSE: XYL) today released a comprehensive white paper titled: “ Digital Water: Industry Leaders Chart the Transformation Journey .”
Examining how digitalisation is transforming the water sector, this important resource provides utility decision makers with actionable learnings to accelerate their adoption of digital solutions and address critical water challenges. The paper also introduces the Digital Water Adoption Curve , a valuable new tool to help utilities assess their digital maturity and map their digital future. Water thought leader and author Will Sarni, CEO, Water Foundry, served as a key author of the report.
Global water challenges, like climate change, population growth, increasing urbanisation and ageing infrastructure, continue to intensify. The latest UN data estimates that 3.6 billion people - almost half the global population - live in areas that are potentially water-scarce at least one month per year and by 2050, more than 5 billion people could suffer water shortages due to climate change, increased demand and polluted supplies. Against this backdrop, water and wastewater utilities are turning to new and innovative solutions including digital technologies, to drive sustainable water management.
“At a time when global water challenges are escalating, digital solutions offer communities around the world bold, new ways to optimise, manage and conserve this most precious resource,” said Kala Vairavamoorthy , IWA Executive Director. “‘Digital Water: Industry Leaders Chart the Transformation Journey’ leverages the insights of IWA members to help utilities learn from their peers, harness the power of digital technologies and enable communities around the world to become more water-secure,” states Kala Vairavamoorthy. “Only together can we shape our water future.”
Patrick Decker , President and CEO of Xylem, said, “The world has to think and act differently about water. There simply is no other choice. Water challenges like scarcity, affordability and resilience are placing millions of human lives at risk, endangering our environment and the global economy, and impeding social progress. These urgent threats are not some far-off problem in the future. They are upon us and growing by the day. We need step-change, and digital innovation is the answer. This paper is a call to action to water stakeholders around the globe. We have the opportunity of a lifetime to solve water and to change history – let’s seize it.”
Valuable lessons from utilities on the digital journey
“Digital Water: Industry Leaders Chart the Transformation Journey” provides valuable insights to water utilities at all stages of digitalisation. The report also shares key utility leaders’ insights in their own voices.
“The world is moving in the direction of technology,” said Richard Appiah Otoo , Chief Technology Officer, Ghana Water Company Limited, one of the nearly 40 utilities that provided input to the white paper. “ Ghana Water experienced a 14 percent increase in revenue after digital technologies increased water bill collection efficiency and provided customers with a mobile billing option.”
Biju George , Executive Vice President, DC Water, commented: “The digital strategy has to become a corporate strategy. It's not an option to sit there and let it happen, you have to plan for it. You have to train your employees towards that, you have to relook at every process. You have to design your systems to give you the data you need to make efficient decisions.”
“If you have any doubt, just try it,” said Claire Falzone , CEO, Nova Veolia-France. “Try small at first if you don't dare to dream big. This is just the beginning of the digital water journey and if you don't adopt digital technologies, someone else will.”
Key take-aways from the report include:
1. Build a holistic digital roadmap and a clear business strategy: Utilities must create internal consensus on how the digital journey will unfold, maintain the customer and business outcomes as focal points throughout the digitalisation process, and educate key stakeholders (consumers, politicians, shareholders, management and employees).
2. Create an innovation culture: Utility operators, IT staff, finance, technicians, executives, and others have to be the scouts for identifying new technologies. However, to drive adoption, utilities must focus on fostering an organisation-wide curiosity and competency for embracing digital innovation.
3. Leverage pilots for an agile mindset: Pilot projects offer a means to explore new technologies, build momentum, and create a more holistic understanding of their physical and financial effects on operations before committing to large-scale implementation.
4. Develop architecture for optimising data use: Developing a data warehouse, where operational data sets become available to functions such as finance, engineering and IT specialists who can use the data to optimise business processes, is critical to creating value from data and effectively digitalising utility infrastructure and connectivity.
NOTES TO EDITORS
About the white paper
The white paper “Digital Water: Industry Leaders Chart the Transformation Journey ” is the first of a series of publications to be developed under the IWA Digital Water Programme. Access the publication here : https://iwa-network.org/projects/digital-water-programme/ .
LAUNCH
The paper is being launched during the 16th IWA Leading Edge Conference on Water and Wastewater Technologies , on Tuesday, 11 June 2019, 10:45 – 11:45 BST - Pentland Auditorium, Edinburgh International Convention Center, Scotland, United Kingdom.
About the IWA Digital Water Programme
The IWA Digital Water Programme aims to act as a catalyst for innovation, knowledge and best practices around digitalisation for the water sector, provide a platform to share experiences and promote leadership in transitioning to digital water solutions, and consolidate lessons to guide the natural evolution from the ‘business as usual’ to achieving a digital water utility. For more information, please visit http://iwa-network.org/projects/digital-water-programme/
About the International Water Association
The International Water Association (IWA) is a network and an international global knowledge hub open to all water professionals and anyone committed to the future of water. With its legacy of over seventy years, it connects water professionals around the world to find solutions to global water challenges as part of a broader sustainability agenda. As a non-profit organization and with a membership in more than 130 countries, the IWA connects scientists with professionals and communities so that pioneering research offers sustainable solutions. In addition, the association promotes and supports technological innovation and best practices through international frameworks and standards. For more information, please visit www.iwa-network.org
About Xylem
Xylem (XYL) is a leading global water technology company committed to developing innovative technology solutions to the world’s water challenges. The Company’s products and services move, treat, analyze, monitor and return water to the environment in public utility, industrial, residential and commercial building services settings. Xylem also provides a leading portfolio of smart metering, network technologies and advanced infrastructure analytics solutions for water, electric and gas utilities. The Company’s approximately 17,000 employees bring broad applications expertise with a strong focus on identifying comprehensive, sustainable solutions. Headquartered in Rye Brook, New York, with 2018 revenue of $5.2 billion, Xylem does business in more than 150 countries through a number of market-leading product brands.
The name Xylem is derived from classical Greek and is the tissue that transports water in plants, highlighting the engineering efficiency of our water-centric business by linking it with the best water transportation of all – that which occurs in nature. For more information, please visit us at www.xylem.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190611005437/en/
Contact:
For more information and/or interviews please contact: Marta Jimenez, marta.jimenez@iwahq.org , +31 631 93 40 81 Katharine Cross, katharine.cross@iwahq.org , +66 924 53 45 13 Raul Glotzbach, raul.glotzbach@iwahq.org , +31 650 63 75 93 Jenny Rider, jenny.rider@xyleminc.com + 1 914 246 7184 Olivia Dempsey, olivia.dempsey@edelman.com +353 1 678 9333
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom